|

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

RECRUITINGPhase 2Sponsored by Dogwood Therapeutics Inc.
Actively Recruiting
PhasePhase 2
SponsorDogwood Therapeutics Inc.
Started2025-02-21
Est. completion2026-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations24 sites
View on ClinicalTrials.gov →

NCT06848348

Summary

A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Male or female patients aged ≥18 years.
* Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
* Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.

Exclusion Criteria:

* Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.
* Patients who have received HAL at any time prior to screening.

Conditions2

CancerChemotherapy Induced Neuropathic Pain

Locations24 sites

Central Recruiting Site
Sheffield, Alabama, 35660
Central Recruiting Site
Glendale, Arizona, 85308
Central Recruiting Site
Fair Oaks, California, 95628
Central Recruiting Site
Fountain Valley, California, 92708
Central Recruiting Site
Los Angeles, California, 91307

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.